Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2008

View Archived Issues

Recent Bayer Schering Pharma patents disclose novel contraceptive agents

Chelsea granted U.K. approval for phase II droxidopa trial in fibromyalgia

Dendreon expects interim data analysis for IMPACT trial in October 2008

GP Pharm completes phase III Lutrate trial in advanced prostate cancer

HT-0712 primate study reveals significant enhancement of long-term memory

Janumet approved in the E.U. for type 2 diabetes

MethylGene and Celgene temporarily suspend new enrollment in MGCD-0103 trial

ProQuin XR achieves first E.U. marketing authorization in Sweden

Medicure able to fund operations until the end of 2008

Teva's acquisition of Bentley Pharmaceuticals completed

Health Canada grants approval to Santhera's Catena in Friedreich's ataxia

Novel radiotracer useful for imaging CB1 type receptors in schizophrenia

Combined statin and biphosphonate treatment shows promise in mouse model of human progeria

[11C]-CUMI-101, a novel radioligand with potential use in imaging 5-HT1A receptors

Vitespen fails to improve recurrence-free survival in high-risk renal cell carcinoma patients

FDA issues nonapprovable letter in response to NexMed's NDA for a topical treatment for ED

New agents for treating psychiatric disorders reported in recent AstraZeneca and Abbott patents

New oncolytic agents imparted in recent patents

Ipsen presents an update on the company's acquisition of Tercica

Roche to acquire Arius Research

Santarus and Depomed enter U.S. promotion agreement for Glumetza for type 2 diabetes

Emergent BioSolutions and University of Oxford form joint venture to develop MVA-85A

FDA grants regulatory clearance to Response Biomedical to market Ramp NT-proBNP test for HF

OncoVista Innovative initiates enrollment in phase I/II study of cordycepin

Talecris' aerosolized alpha1-antitrypsin designated orphan drug in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...